ESCAPHARM: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
ESCAPHARM
Largest movements
- Receivables within one year +€165,912
up €165,912 (+91.3%), from €181,642 to €347,555
of which Other amounts receivable: +€116,905
- Tangible fixed assets -€17,854
down €17,854 (-35.0%), from €51,071 to €33,217
- Reserves +€105,771
up €105,771 (+15.2%), from €695,415 to €801,186
of which Distributable reserves: +€105,771
- Other debts +€87,266
up €87,266 (+59.3%), from €147,183 to €234,448
- Debts after one year -€33,217
down €33,217 (-10.7%), from €311,442 to €278,225
- Accrued charges and deferred income -€29,969
down €29,969 (-100.0%), from €29,969 to €0
- Gross operating margin +€37,898
up €37,898 (+19.4%), from €195,640 to €233,538
- Taxes +€12,327
up €12,327 (+28.7%), from €42,973 to €55,300
- Other operating charges +€7,531
up €7,531 (+1703.7%), from €442 to €7,973
- Depreciation +€7,081
up €7,081 (+65.7%), from €10,772 to €17,854
- Financial income +€5,397
new in 2025: €5,397
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,309,206 | €1,455,689 | +€146,484 | +11.2% |
| Fixed assets | 21/28 | €1,092,671 | €1,074,817 | -€17,854 | -1.6% |
| Tangible fixed assets | 22/27 | €51,071 | €33,217 | -€17,854 | -35.0% |
| Furniture and vehicles | 24 | €51,071 | €33,217 | -€17,854 | -35.0% |
| Financial fixed assets | 28 | €1,041,600 | €1,041,600 | = | 0.0% |
| Current assets | 29/58 | €216,535 | €380,872 | +€164,337 | +75.9% |
| Amounts receivable within one year | 40/41 | €181,642 | €347,555 | +€165,912 | +91.3% |
| Trade receivables | 40 | €181,642 | €230,650 | +€49,007 | +27.0% |
| Other amounts receivable | 41 | €0 | €116,905 | +€116,905 | |
| Cash at bank and in hand | 54/58 | €32,780 | €32,849 | +€70 | +0.2% |
| Deferred charges and accrued income | 490/1 | €2,113 | €468 | -€1,645 | -77.8% |
| Total equity and liabilities | 10/49 | €1,309,206 | €1,455,689 | +€146,484 | +11.2% |
| Equity | 10/15 | €715,415 | €821,186 | +€105,771 | +14.8% |
| Contributions | 10/11 | €20,000 | €20,000 | = | 0.0% |
| Reserves | 13 | €695,415 | €801,186 | +€105,771 | +15.2% |
| Non-distributable reserves | 130/1 | €2,000 | €2,000 | = | 0.0% |
| Reserves not available under the articles | 1311 | €2,000 | €2,000 | = | 0.0% |
| Distributable reserves | 133 | €693,415 | €799,186 | +€105,771 | +15.3% |
| Profit (loss) carried forward | 14 | €0 | €0 | = | |
| Amounts payable | 17/49 | €593,791 | €634,504 | +€40,713 | +6.9% |
| Amounts payable after more than one year | 17 | €311,442 | €278,225 | -€33,217 | -10.7% |
| Financial debts | 170/4 | €311,442 | €278,225 | -€33,217 | -10.7% |
| Amounts payable within one year | 42/48 | €252,380 | €356,279 | +€103,899 | +41.2% |
| Current portion of amounts payable after more than one year | 42 | €39,562 | €33,217 | -€6,345 | -16.0% |
| Trade debts | 44 | €4,616 | €3,452 | -€1,163 | -25.2% |
| Suppliers | 440/4 | €4,616 | €3,452 | -€1,163 | -25.2% |
| Advances received on contracts in progress | 46 | - | €14,520 | +€14,520 | |
| Taxes, remuneration and social security | 45 | €61,019 | €70,641 | +€9,622 | +15.8% |
| Taxes | 450/3 | €61,019 | €70,641 | +€9,622 | +15.8% |
| Other amounts payable | 47/48 | €147,183 | €234,448 | +€87,266 | +59.3% |
| Accrued charges and deferred income | 492/3 | €29,969 | €0 | -€29,969 | -100.0% |
| Non-recurring operating income | 76A | - | €413 | +€413 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €10,772 | €17,854 | +€7,081 | +65.7% |
| Other operating charges | 640/8 | €442 | €7,973 | +€7,531 | +1703.7% |
| Gross operating margin | 9900 | €195,640 | €233,538 | +€37,898 | +19.4% |
| Operating profit (loss) | 9901 | €184,426 | €207,711 | +€23,285 | +12.6% |
| Financial income | 75/76B | - | €5,397 | +€5,397 | |
| Recurring financial income | 75 | - | €5,397 | +€5,397 | |
| Financial charges | 65/66B | €36,386 | €38,416 | +€2,031 | +5.6% |
| Recurring financial charges | 65 | €36,386 | €38,416 | +€2,031 | +5.6% |
| Profit (loss) for the period before taxes | 9903 | €148,040 | €174,692 | +€26,652 | +18.0% |
| Income taxes | 67/77 | €42,973 | €55,300 | +€12,327 | +28.7% |
| Profit (loss) for the period | 9904 | €105,067 | €119,392 | +€14,325 | +13.6% |
| Profit (loss) for the period to be appropriated | 9905 | €105,067 | €119,392 | +€14,325 | +13.6% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 3 October 2026 via checked.be.